These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33329783)

  • 1. A semi-compartmental model describing the pharmacokinetic-pharmacodynamic relationship.
    Ki S
    Anesth Pain Med (Seoul); 2020 Jan; 15(1):1-7. PubMed ID: 33329783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.
    Louizos C; Yáñez JA; Forrest ML; Davies NM
    J Pharm Pharm Sci; 2014; 17(1):34-91. PubMed ID: 24735761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A semicompartmental modeling approach for pharmacodynamic data assessment.
    Kowalski KG; Karim A
    J Pharmacokinet Biopharm; 1995 Jun; 23(3):307-22. PubMed ID: 8834198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methodological issues in pharmacokinetic-pharmacodynamic modelling.
    Bellissant E; Sébille V; Paintaud G
    Clin Pharmacokinet; 1998 Aug; 35(2):151-66. PubMed ID: 9739481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of parametric with semiparametric analysis of the concentration versus effect relationship of metocurine in dogs and pigs.
    Shafer SL; Varvel JR; Gronert GA
    J Pharmacokinet Biopharm; 1989 Jun; 17(3):291-304. PubMed ID: 2810069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of multiple doses and pharmacodynamic system analysis to distinguish between dispositional delays and time-variant pharmacodynamics.
    Gastonguay MR; Schwartz SL
    Pharm Res; 1994 Dec; 11(12):1825-8. PubMed ID: 7899250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic modeling: time-dependent protein binding--an alternative interpretation of clockwise and counterclockwise hysteresis.
    Pedraz JL; Calvo B; Smithers JA; Thompson GA
    J Pharm Sci; 1992 Mar; 81(3):232-6. PubMed ID: 1640359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rocuronium pharmacodynamic models for published five pharmacokinetic models: age and sex are covariates in pharmacodynamic models.
    Masui K; Ishigaki S; Tomita A; Otake H
    J Anesth; 2018 Oct; 32(5):709-716. PubMed ID: 30099599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semiparametric approach to pharmacokinetic-pharmacodynamic data.
    Verotta D; Beal SL; Sheiner LB
    Am J Physiol; 1989 Apr; 256(4 Pt 2):R1005-10. PubMed ID: 2705568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of a variable direction hysteresis minimization approach in describing the central nervous system pharmacodynamic effects of alfentanil in rabbits.
    Modi NB; Veng-Pedersen P
    J Pharm Sci; 1994 Mar; 83(3):351-6. PubMed ID: 8207680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.
    Minto CF; Schnider TW; Gregg KM; Henthorn TK; Shafer SL
    Anesthesiology; 2003 Aug; 99(2):324-33. PubMed ID: 12883405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect pharmacodynamic response models do not require any parametric pharmacokinetic model to be fitted to effect-time data.
    Piotrovsky VK
    Methods Find Exp Clin Pharmacol; 1997 Dec; 19(10):723-9. PubMed ID: 9542723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients.
    Triggs EJ; Charles BG; Contin M; Martinelli P; Cortelli P; Riva R; Albani F; Baruzzi A
    Eur J Clin Pharmacol; 1996; 51(1):59-67. PubMed ID: 8880053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic modelling of insulin: comparison of indirect pharmacodynamic response with effect-compartment link models.
    Lin S; Chien YW
    J Pharm Pharmacol; 2002 Jun; 54(6):791-800. PubMed ID: 12078995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic modeling of the new steroid hypnotic eltanolone in healthy volunteers.
    Hering WJ; Ihmsen H; Langer H; Uhrlau C; Dinkel M; Geisslinger G; Schüttler J
    Anesthesiology; 1996 Dec; 85(6):1290-9. PubMed ID: 8968176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.
    Gumbleton M; Oie S; Verotta D
    Br J Clin Pharmacol; 1994 Nov; 38(5):389-400. PubMed ID: 7893578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Allometric Model of Remifentanil Pharmacokinetics and Pharmacodynamics.
    Eleveld DJ; Proost JH; Vereecke H; Absalom AR; Olofsen E; Vuyk J; Struys MMRF
    Anesthesiology; 2017 Jun; 126(6):1005-1018. PubMed ID: 28509794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic/Pharmacodynamic Analysis of Metformin using Different Models in Diabetic Rats.
    Li X; Chen Y; Zhao Z; Lu W; Zhou T
    Drug Res (Stuttg); 2016 Oct; 66(10):547-554. PubMed ID: 27463030
    [No Abstract]   [Full Text] [Related]  

  • 19. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena.
    Sharma A; Ebling WF; Jusko WJ
    J Pharm Sci; 1998 Dec; 87(12):1577-84. PubMed ID: 10189270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model.
    Fuseau E; Sheiner LB
    Clin Pharmacol Ther; 1984 Jun; 35(6):733-41. PubMed ID: 6329584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.